Abstract
Insulin formulations with diverse oligomerization states are the hallmark of interventions for the treatment of diabetes. Here using single-molecule recordings we firstly reveal that insulin oligomerization can operate via monomeric additions and secondly quantify the existence, abundance and kinetic characterization of diverse insulin assembly and disassembly pathways involving addition of monomeric, dimeric or tetrameric insulin species. We propose and experimentally validate a model where the insulin self-assembly pathway is rerouted, favoring monomeric or oligomeric assembly, by solution concentration, additives and formulations. Combining our practically complete kinetic characterization with rate simulations, we calculate the abundance of each oligomeric species from nM to mM offering mechanistic insights and the relative abundance of all oligomeric forms at concentrations relevant both for secreted and administrated insulin. These reveal a high abundance of all oligomers and a significant fraction of hexamer resulting in practically halved bioavailable monomer concentration. In addition to providing fundamental new insights, the results and toolbox presented here can be universally applied, contributing to the development of optimal insulin formulations and the deciphering of oligomerization mechanisms for additional proteins.
Originalsprog | Engelsk |
---|---|
Artikelnummer | 178 |
Tidsskrift | Communications Biology |
Vol/bind | 6 |
Udgave nummer | 1 |
Antal sider | 14 |
ISSN | 2399-3642 |
DOI | |
Status | Udgivet - 2023 |
Bibliografisk note
Funding Information:N.S.H. and K.J.J. acknowledge funding from Villum foundation center BIONEC (grant 18333). N.S.H. acknowledges funding from Villum foundation project (grant 40801), Carlsberg Foundation Distinguished Associate Professor Program (CF16-0797), and the NovoNordisk Center for Biopharmaceuticals and Biobarriers in Drug Delivery (NNF16OC0021948). The Novo Nordisk Foundation Center for Protein Research (CPR) is funded by a generous donation from the Novo Nordisk Foundation (grant no. NNF14CC0001). N.S.H. is a member of the Integrative Structural Biology Cluster (ISBUC) at the University of Copenhagen.
Funding Information:
N.S.H. and K.J.J. acknowledge funding from Villum foundation center BIONEC (grant 18333). N.S.H. acknowledges funding from Villum foundation project (grant 40801), Carlsberg Foundation Distinguished Associate Professor Program (CF16-0797), and the NovoNordisk Center for Biopharmaceuticals and Biobarriers in Drug Delivery (NNF16OC0021948). The Novo Nordisk Foundation Center for Protein Research (CPR) is funded by a generous donation from the Novo Nordisk Foundation (grant no. NNF14CC0001). N.S.H. is a member of the Integrative Structural Biology Cluster (ISBUC) at the University of Copenhagen.
Publisher Copyright:
© 2023, The Author(s).